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Abstract
The identification of genetic and epigenetic alterations from primary tumor cells has become a common method to identify
genes critical to the development and progression of cancer. We seek to identify those genetic and epigenetic aberrations
that have the most impact on gene function within the tumor. First, we perform a bioinformatic analysis of copy number
variation (CNV) and DNA methylation covering the genetic landscape of ovarian cancer tumor cells. We separately examined
CNV and DNA methylation for 42 primary serous ovarian cancer samples using MOMA-ROMA assays and 379 tumor samples
analyzed by The Cancer Genome Atlas. We have identified 346 genes with significant deletions or amplifications among the
tumor samples. Utilizing associated gene expression data we predict 156 genes with altered copy number and correlated
changes in expression. Among these genes CCNE1, POP4, UQCRB, PHF20L1 and C19orf2 were identified within both data
sets. We were specifically interested in copy number variation as our base genomic property in the prediction of tumor
suppressors and oncogenes in the altered ovarian tumor. We therefore identify changes in DNA methylation and expression
for all amplified and deleted genes. We statistically define tumor suppressor and oncogenic features for these modalities
and perform a correlation analysis with expression. We predicted 611 potential oncogenes and tumor suppressors
candidates by integrating these data types. Genes with a strong correlation for methylation dependent expression changes
exhibited at varying copy number aberrations include CDCA8, ATAD2, CDKN2A, RAB25, AURKA, BOP1 and EIF2C3. We
provide copy number variation and DNA methylation analysis for over 11,500 individual genes covering the genetic
landscape of ovarian cancer tumors. We show the extent of genomic and epigenetic alterations for known tumor
suppressors and oncogenes and also use these defined features to identify potential ovarian cancer gene candidates.
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Introduction
In the United States, there will be over 22,000 new cases of
ovarian cancer in 2011. Of those, approximately 14,000 will
succumb to the disease. In order to better treat these women and
improve survival, our goal is to determine the molecular changes
that have occurred in the patients’ tumors, and to be able to
interpret the significance these changes have on the growth and
development of the tumor. This aberrant growth is a result of
chromosomal abnormalities and epigenetic variations [1,2]. In
addition, generally low rates of somatic nucleotide mutation in
ovarian cancer as compared to other solid tumors suggest an
increased significance of copy number and epigenetic aberrations.
This type of regulation has been shown to affect many tumor
suppressors and oncogenes pertaining to ovarian cancer [3].
Copy number variations (CNV) are a common occurrence in all
forms of cancer [4,5,6,7,8,9]. A typical cancer sample exhibits an
average of 17% amplifications and 16% deletions within an entire
genome. Somatic copy number alterations have been shown to
significantly affect pathways involving kinase function, cell cycle
regulation, the Myc and NF-kB networks and apoptosis [4].
Detection of these alterations and identification of the specific
genes responsible for cancer proliferation can help to molecularly
subtype cancers and lead toward more individualized cancer-type
specific therapies [7,10,11,12,13,14,15,16,17,18,19,20].
Epigenetic properties of the cancer genome correlate with the
development and function of the cancer cell [1,21,22,23,24].
Specifically, DNA methylation at gene promoter regions can
regulate the gene expression of various oncogenes and tumor
suppressors [25,26,27]. It has been proposed that total DNA
cytosine 5C-methylation between normal and cancer cells appears
to be redistributed to specific CpG loci in the cancer cell [28,29].
Loss of function or transcriptional silencing via hypermethylation
has been identified for tumor suppressor genes, while hypomethy-
lation has been attributed to oncogenesis and the loss of imprinting
properties of certain cancer related alleles [1,30].
Tumor suppressor and oncogene genomic and epigenetic
features are highly variable within ovarian cancer [3]. Known
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tumor suppressors and oncogenes do not equally contribute to the
development of the cancer. We hope to identify those genetic and
epigenetic aberrations that have the most impact on gene function
within the tumor. Many of the current bioinformatics protocols
employ only single modal analysis to determine gene function of a
particular tumor type. A genome wide approach combining
multiple sources of genetic aberration data is necessary for the
prediction of possibly consistent and epigenetically integrated
pathways that function in tumorigenesis. We performed a broad
bioinformatics analysis of copy number variation, expression and
epigenetic information to identify potential tumor suppressors and
oncogenes associated to serous ovarian cancer. Analyzing 42
independent serous ovarian cancer samples and taking advantage
of The Cancer Genome Atlas (TCGA; http://tcga.cancer.gov)
[31] data to compare and enhance our protocol, we identify
abnormal DNA copy number with correlated changes in
methylation and expression for serous ovarian cancer genes. The
combination of epigenetic and expression data analysis can
possibly provide information specific to the molecular basis of
cancer and cancer subtypes and elucidate the genes driving
various tumors [28,32,33,34,35]. Thereby, eventually allowing
clinicians to incorporate these types of comprehensive multimodal
data analyses into tumor biospecific based diagnostics and
pathway directed therapeutics [36].
Methods
Patient Samples (MSKCC Data)
Tumor DNA from 42 patients with newly diagnosed, untreated,
advanced stage, serous ovarian carcinomas seen at the Memorial
Sloan Kettering Cancer Center between the period May 1992–
February 2003 were included in this study. The samples were
collected under research protocols approved by the Memorial
Sloan-Kettering Cancer Center IRB. The study on patient
samples and analysis of all sample data complied with the
guidelines of the Memorial Sloan-Kettering Cancer Center IRB
and was approved by the Memorial Sloan-Kettering Cancer
Center IRB. Patients individually provided written informed
consent to use their specimens for research purposes. In addition,
we used 7 ovarian tissue normal samples obtained from The
Cooperative Human Tissue Network, a repository of tissue and
tumor material run by the National Institutes of Health. We refer
to this patient and normal sample set as the MSKCC data set.
Copy Number Detection via Representational
Oligonucleotide Microarray Analysis (ROMA)
The ROMA protocol as previously outlined [11,15,37] was
performed on a high-density oligonucleotide array containing
,85,000 features manufactured by Nimblegen Systems Inc.
Briefly, complexity-reduced representations [38] consisting of
small (200–1200 bp) fragments, generated by cleavage of DNA
samples with the restriction endonuclease BglII, were amplified by
adapter-mediated PCR of genomic DNA [11]. DNA samples
(2 mg) were labeled either with Cy5-dCTP or Cy3-dCTP using
Amersham-Pharmacia MegaPrime labeling kit and competitively
hybridized to each other on the same slide [11]. Hybridizations
consisted of 35 mL of hybridization solution (37% formamide, 46
SSC, 0.1%SDS, and labeled DNA). Microarry application and
hybridization was performed as previously reported [11]. Scanned
on an Axon GenePix 4000B scanner using a pixel size of 5 mm and
all data was imported into S-Plus 2000 analysis software
(Insightful, Seattle, WA). The normalized log ratios from each
experiment were averaged per segmentation. We then applied the
CBS (Circular Binary Segmentation) algorithm to this data. The
CBS segmentation method is the circular binary segmentation
algorithm as described in Olshen, AB. et. al. [39]. As in prior
analysis, CNV segments are defined as regions of statistically
combined probe (marker) intensities calculated by the CBS
algorithm [39,40]. All general analysis and statistics were
computed using S-plus, R packages and individual Perl/Python
scripts. All ROMA data is MIAME compliant and can be found in
the GEO database (http://www.ncbi.nlm.nih.gov/geo/) for the
subseries accession number GSE28013.
Methylation Detection via Representational
Oligonucleotide Microarray Analysis (MOMA)
The MOMA protocol was performed as previously described
[41,42]. The MOMA methylation detection array has been
performed and validated on cell lines and breast cancer tumor
samples. Annotated genomic CpG island locations were obtained
from the UCSC genome browser. At the time of the experiment
the genome contained 26,219 CpG islands in the range of 200–
2000 bp. These CpG island locations were covered by MspI
restriction fragmentation. Arrays were manufactured by Nimble-
gen Systems Inc. using the 390,000 probes format. The CpG
island annotation from the human genome build 33 (hg17) was
used to design a 50-mer tiling array. The primary restriction
endonuclease used is MspI. After the digestion linkers were ligated
and the material is cleaned by phenol chloroform, precipitated,
centrifuged, and resuspended. The material is divided in two, half
being digested by the endonuclease McrBc according to
specification by New England Biolabs and the other half being
mock digested. Procedures for hybridization and washing were
reported previously [41]. The procedure was performed in
duplicate with a dye-swap for the second experiment. The labels
were swapped between the McrBc treated and mock samples. For
each probe, the geometric mean of the ratios (GeoMeanRatio) of
McrBc treated and control samples were then calculated per
experiment and its associated dye swap. Microarray images were
scanned on GenePix 4000B scanner and data extracted using
Nimblescan software (Nimblegen Systems Inc). The GeoMeanRa-
tios of all the samples in a data set were then normalized using a
quantile normalization method [43]. All general analysis and
statistics were computed using S-plus, R packages and individual
Perl/Python scripts. All MOMA data is MIAME compliant and
be found in the GEO database (http://www.ncbi.nlm.nih.gov/
geo/) for the subseries accession number GSE27940.
Gene Expression Analysis for Human Ovarian Tumor
Samples
Gene Expression data was performed using the Affymetrix
Human Genome U133A array: GEO platform identifier GPL96.
RNA was isolated using the trizol protocol. RNA is converted into
cDNA and the double-stranded cDNA is used as the template in
an in-vitro transcription reaction containing biotinylated CTP and
UTP in addition to the four unmodified ribonucleoside triphos-
phates. The standard affymetrix protocol is applied. Final signal
intensities are processed using the RMA normalization method in
the affy package of R Bioconductor 2.5. All array data is MIAME
compliant and corresponding CEL files can be found in the GEO
database (http://www.ncbi.nlm.nih.gov/geo/) for the subseries
accession number GSE27943.
Cross-modal Analysis of The Cancer Genome Atlas Data
(TCGA data)
Copy number variation data for primary ovarian tumors was
downloaded from TCGA (http://tcga.cancer.gov/) and CBS [39]
Genomic and Epigenetic Features in Ovarian Cancer
PLoS ONE | www.plosone.org 2 December 2011 | Volume 6 | Issue 12 | e28503
data files from the Agilent SurePrint G3 Human 1 M CGH
(Comparative Genomic Hybridization) Microarray with the label
mskcc.org_OV.CGH-161M_G4447A were analyzed. The CBS
processed data from the TCGA was then annotated with the
UCSC Genome Browser hg18 assembly information to assign
copy number variation seg.mean values per gene per sample. For
the purpose of studying CNV per gene we limited our data to one
complete CBS segment per gene per sample. Therefore, if a gene
locus is partially covered by two or more CBS segments per sample
we did not include it in our analysis. Only if a complete gene locus
was within a sample CBS segment was it included into our
analysis. Furthermore, we excluded any CBS segment with an
informative (num.info) value of less than 4. Additionally, in order
to capture significant CNV we only analyzed samples in 90% of
the data excluding 5% of the data closest to a seg.mean of 0 from
the positive and negative value distribution. TCGA methylation
data was obtained from the jhu-usc.edu_OV.HumanMethyla-
tion27.2.lvl-3 data files for each corresponding tumor and normal
sample. This is from the Illumina Infinium Human27-methylation
assay. A final mean beta value for genes with 2 or more probes was
calculated per gene per sample. Finally, the TCGA expression
data used for this analysis was from the broad.mit.edu HT_HG-
U133A gene expression file for each corresponding tumor and
normal sample run on the Affymetrix GeneChip HT Human
Genome U133A array. We examined 379 samples from the
TCGA that were present at the time of our analysis. Prior to the
final submission of our manuscript The Cancer Genome Atlas has
made public their preliminary report on ovarian carcinoma [31].
Our use of the TCGA data set is to enhance and compare our
tumor suppressor and oncogene discovery protocol that we
applied to the MOMA-ROMA (MSKCC) dataset. We acknowl-
edge any similar findings we have made using our protocol on the
TCGA dataset with that found in the recent TCGA publication.
Bioinformatic Analysis of MSKCC Copy Number (ROMA),
DNA Methylation (MOMA) and Expression Data
All analysis was performed using Perl, Python, Matlab, and R
packages. Our strategy was to examine the epigenetic and
genomic features for possible tumor suppressors and oncogenes
in primary ovarian tumors. With the base feature being copy
number variation we examine methylation and expression data for
each gene under amplified or deleted copy number conditions.
Therefore, an oncogene is classified as an amplified gene having
low methylation and elevated expression (Figure 1). This same
amplified oncogene may be epigenetically regulated through
hypermethylation in ovarian cancer resulting in a decreased
expression even if copy number is amplified. Conversely, a tumor
suppressor can have lowered copy number variation and be
hypermethylated resulting in decreased expression or regulated
through hypomethylation allowing for its expression under
lowered CNV conditions (Figure 1). ROMA fragments were
attributed to genes using the UCSC Genome Browser hg17
assembly. We identified through sample comparison between the
TCGA platform and the ROMA platform (for which 7 samples
were in common) a ROMA platform-specific threshold of ,0.0
seg.mean that captures a maximum percentage of deleted genes
while maintaining a minimum false positive percentage of
amplified or neutral copy genes. Final gene methylation
assignment was performed using the maximum probe value for
each MOMA fragment and the maximum MOMA fragment
value was attributed to the closest gene. The Wilcoxon signed-rank
test was used to calculate enrichment p-values for CNV and
expression data and the Benjamini-Hochberg (BH) method was
used for the multitest adjustment and False Discovery Rate (FDR)
control. Euclidean distances were calculated between normal and
tumor samples for methylation and expression data points for all
genes in both the MSKCC and TCGA data sets. In the case of the
MSKCC data set when sufficient normal sample expression data
was not available, a 506bootstrap sampling was performed using
the TCGA normal samples expression data per gene. Single
variate and Hotelling multivariate t-tests were performed on these
distances to calculate all p-values when performing the methyla-
tion and expression analysis at varying copy number values, with
statistical multiple test FDR adjustments as above. In order to
identify likely functional and pathway changes captured by our
feature based gene analysis we tested whether the membership of
predicted MSKCC genes in each feature class within a total of 173
KEGG biological pathways was proportional to their size. This
translates to identifying pathways whose gene membership in each
feature class deviates significantly from the null, as defined by a
hypergeometric distribution. The final list of significant pathways
was chosen after controlling the false discovery rate by Benjamini-
Hochberg multiple testing correction. Data analysis scripts and
further analysis information can be found in Analysis S1.
Results
Ovarian Tumor Copy Number Aberrations and DNA
Methylation
We first individually analyzed both the copy number variation
and DNA methylation for each gene by chromosomal position in
42 serous primary ovarian tumors provided by the Gynecology
Research Laboratory at Memorial Sloan-Kettering Cancer Center
(MSKCC data set) using Representational Oligonucleotide
Microarray Analysis (ROMA) [37,44] and Methylation detection
Oligonucleotide Microarray Analysis (MOMA) [41,42]. The
amplified and deleted breakpoint loci cover a total of 561 regions
among all samples (Figure 2). ROMA identifies 205 deletion and
356 amplification breakpoints. Breakpoints were defined as
regions between each segment (statistically combined probe
intensities) calculated using the CBS (circular binary segmentation
[39,40]) method. Among the 42 tumor samples, we find an
average of 76 CBS calculated segments per chromosome.
Segmentation count per chromosome corresponded with chro-
mosome size except for chromosomes 8, 11, 12, 17, 19, and 20
where segmentation density was greater than normalized for
chromosome size and less for chromosomes 6, 9, 10, 14, 15, 16,
and 18. The greatest variability of copy number variation (as
measured by CBS segmentation mean values) among all samples
occurs in chromosomes 19, 2, 10 and 4, respectively (Figure S1).
The most frequent deletions (.10% tumor samples) were observed
in loci; chr4:q25-q35.2, chr7:p22.3-p15.3, chr8:p23.3-p21.1,
chr13q12.11-q34, chr14q32.2-q32.33, chr15q13.3-q21.1,
chr16q11.2-q24.3, chr17p13.3-q25.3, chr19:q13.2-q13.43 and
chr22:q11.21-q13.33 (Table 1 provides the percentage of all
samples deleted within a loci). The most frequently amplified
(.10% tumor samples) loci within all chromosomes among all 42
tumor samples are; chr1:p34.4-p34.1, chr1:q21.1-q21.2,
chr3:q13.2-q23, chr8:q11.22-q24.3, chr19:q12-q13.12 and
chr20:q13.12-q13.2 (Table 1). Three breakpoint symmetry loci
(amplifications and deletions at similar genomic positions in
multiple samples) were found; chr17:q11.2-q21.32, chr19:q13.12-
q13.2 and chr21:q21.3–22.13. Comparing the ROMA results
(Table 1) with copy number data of normal individuals found in
HapMap [45] shows no overlap with the few amplified regions
found in the HapMap normal data set. Overlapping regions of
deletion between our CNV results and HapMap are 8p23 and
22q11.23 where both regions show frequent heterozygous loss. We
Genomic and Epigenetic Features in Ovarian Cancer
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then analyzed the DNA methylation at CpG islands using the
same 42 primary ovarian tumors and 7 normal tissue samples
(Figure 3). We compiled methylation values for 11,978 gene
promoter regions covering 22 chromosomes. When directly
compared to normal tissue a total of 68 genes were found to be
ranked as hypermethylated and 19 ranked as hypomethylated
within 10% of the entire normal to tumor ratio distribution (Table
S1). The genes exhibiting methylation values above normal
samples include the oncogene PHOX2B, the neuroblastoma
associated gene ALX3, the commonly methylated PCDHa gene
cluster, POU4F2, REXO1L1, BAPX1, and the potassium-
channel KCNJ8. Specifically, REXO1L1, (RNA exonuclease)
shows high levels of methylation in both tumor and normal
samples however there is a 56% increase of methylation in tumor
samples. Genes with the lowest tumor to normal methylation
ratios include the chromosome 4 variant of the oncogenic
promoting gene ubiquitin hydrolase DUB3 (19% decrease) and
CAPS (oncogene implicated in endometrial cancer, 25%
decrease). Other hypomethylated genes as compared to normal
samples included; RNPC3, USP37, LDHD, GJB4 (gap junction
protein), LCN8 (implicated in metastasis) and CGB1 (chorionic
gonadotropin, beta polypeptide 1) (Table S1).
Correlations of Gene Expression with Copy Number
Variation or DNA Methylation
We separately examined the dependency of gene expression (via
the Affymetrix Human Genome U133A array, see Methods) on
copy number amplification, copy number deletion and promoter
methylation in ovarian cancer tumors. We first compared the
distribution of gene expression for discrete high and low CNV
genes found in our MSKCC data set and TCGA data set. The two
data sets showed similar tendencies in expression distribution for
genes with high and low copy number variation (Figure 4, Figure
S2). As the copy number variation increases from deletion to
amplification the average gene expression also increases (Figure 4).
We therefore show a correlation between an increase in total gene
expression with the amplification of gene copy number in primary
ovarian tumors. Additionally, we measured the cumulative
distribution of gene expression for deleted and amplified genes.
The cumulative distribution is the total percentage of genes found
below a dynamic expression threshold. If genes with a low CNV
(deleted) are more under expressed than genes with a higher CNV
(amplified and over expressed) the cumulative distribution curve
results in a steeper rise at lower expression values for deleted genes
(indicating a greater percentage of genes found with lower
expression values). A maximum cumulative expression difference
between 7–17% is observed for genes with low copy number
compared to genes with high copy number (Figure S3). Next, we
performed expression to CNV correlation per gene for all tumor
samples in both the MSKCC data set and TCGA data set. We
discovered 124 genes with positive CNV to expression Pearson
correlation coefficient limits of $0.8 in the TCGA data set (p-
values,1.0610210, Table S2B). The seg.mean amplification and
deletion range for the MSKCC data set is not as great as observed
in the TCGA data set (Figures S1 and S2) and therefore fewer
genes are captured with significant CNV to expression correla-
tions. However, we are able to identify 32 genes with Pearson
correlation values$0.6 (p-values,4.061025, Table S2A) with 18
of the 32 genes also identified in the TCGA data set (Table S2A).
Greater gene expression differences between normal and tumor
samples are not observed until we rely only on those samples
containing genes with extreme amplifications and deletions
(Figure 4). Therefore our approach to identify genes with altered
copy number variation correlated to expression was to examine
the expression values of genes within high and low copy number
seg.mean values and compare the expression of those genes to that
of normal tissue samples. In an event where there is copy number
aberration in normal samples this same type of correlation would
be observed. We examined only tumor samples since the
magnitude and extent of copy number alterations is more
significantly detected through our protocol. Initially we calculated
the average expression value for each gene where 20% of the
tumor samples showed a CNV value of above 0.50 seg.mean or
below 20.50 seg.mean and also filtered out the genes for which
the normal expression was not within the standard deviation (the
default TCGA CNV thresholds were used which correspond to at
least one amplified or deleted copy and with the ability to capture
as many altered CNV samples per gene as possible). This strict
Figure 1. Genomic and epigenetic features of tumor suppressors and oncogenes. Copy number variation is the base genomic feature for
our identification of tumor suppressor and oncogenic gene properties in ovarian cancer. An oncogene can be overexpressed under amplified copy
number and low methylation, while hypermethylation can be used for regulating expression in a gene amplified state. Similarly, decreased tumor
suppressor expression can be the result of partial copy number loss with hypermethylation. Tumor suppressors may also possibly be regulated via
hypomethylation in a copy number deleted stated. Our analysis is modeled for such properties and first examines the CNV per gene and then
attributes epigenetic alteration for each copy number aberration with gene expression.
doi:10.1371/journal.pone.0028503.g001
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criteria of 20% of TCGA tumor samples captured 21 genes (Table
S3). These 21 genes such as CCNE1 and GSTT1 represent the
most altered CNV genes in the tumor samples with differential
expression as compared to tissue normal samples in the TCGA
data set. However this approach is greatly dependent on the
normal gene average expression levels. For TCGA, at the time of
our analysis expression information was only available for 8
samples designated as normal. Therefore, a gene such as MYC
(most often over expressed in tumor cells) which has a mean
sample expression value of 8.93 in the eight TCGA normal
samples (Figure S4) and a mean tumor sample expression value of
7.75 (from 339 tumor samples) is not observed by this method. By
performing tumor sample specific analysis we may not fully
eliminate these variations but hope to limit their magnitude.
So as not to rely on the small normal tissue sampling for
expression values, we performed a Wilcoxon rank test only on
expression values from a minimum 20% of the tumor samples
within very low and high gene copy number seg.mean thresholds.
In the TCGA tumor data set this produced a set of 54 genes within
a false discovery rate of 5% at seg.mean values of 1.25 and 20.50
for high and low copy number variation, respectively (Table 2,
Table S4). The number of genes captured is dependent on the
high copy number segmentation mean value used as a filtering
threshold (while maintaining a set low copy threshold at 20.50,
thereby at minimum capturing a loss of heterozygosity per gene
[8]; Figure S5). A total of 1114 genes are captured (FDR,0.05) at
a lower CNV threshold of 0.8 seg.mean (Figure S5). With the
Wilcoxon rank test we find genes such as MYC, CCNE1, KRAS,
NDRG1, MLL4 and MTSS1 for which data set specific normal
tissue expression may not be significantly different from all tumor
samples but is variable between low and high copy number tumor
samples. Conservative threshold limitations of 20% tumor sample
inclusion resulted in the identification of genes from extreme CNV
loci such as in chromosomes 1, 8, and 19. Of interest, transcription
factor CEPBG was found to have good CNV to expression
correlation and also expression and methylation correlation in the
MSKCC data set. Similarly, performing the Wilcoxon rank test on
MSKCC tumor samples at a high copy number threshold $0.5
and a low copy number ROMA platform-specific threshold ,0.0
(see Methods) we captured 62 genes at a false discovery rate#0.05
(Table 2, Table S4). Genes identified in the MSKCC data set were
from similar genomic loci as those found in the TCGA data set.
Five genes were predicted from both data sets: CCNE1, POP4,
UQCRB, PHF20L1 and C19orf2 (Table 2). We have integrated
the expression data with CNV to determine the genes that are
more likely to be candidates as functioning cancer genes with
potential tumor suppressor and oncogenic CNV-expression
features. This makes the number of genes in further studies more
approachable for functional validation of genes affected by genetic
aberrations.
We also analyzed the classical dependence of DNA methylation
in gene promoter regions with that of gene expression.
Figure 2. Amplification and deletion breakpoint variability
among ROMA segments. Breakpoint positions of copy number
variability (deletions depicted in blue, amplifications depicted in red) in
22 chromosomes are shown as determined from ROMA generated
segmentation data. The initial altering deletion or amplification
genomic position is depicted from all 42 ovarian tumor cancer samples.
doi:10.1371/journal.pone.0028503.g002
Table 1. Chromosomal deletions and amplifications in
ovarian cancer tumors*.
Location Frequency
Deletions
chr4:q25-q35.2 11%
chr7:p22.3-p15.3 12%
chr8:p23.3-p21.1 15%
chr13q12.11-q34 19%
chr14q32.2-q32.33 12%
chr15q13.3-q21.1 14%
chr16q11.2-q24.3 20%
chr17p13.3-q25.3 50%
chr19:q13.2-q13.43 20%
chr22:q11.21-q13.33 67%
Amplifications
chr1:p34.4-p34.1 12%
chr1:q21.1-q21.2 19%
chr3:q13.2-q23 12%
chr8:q11.22-q24.3 35%
chr19:q12-q13.12 20%
chr20:q13.12-q13.2 15%
*Sample frequency for the most common chromosomal deletions and
amplifications found using ROMA in the MSKCC 42 ovarian cancer sample set.
doi:10.1371/journal.pone.0028503.t001
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Methylation data exhibits poorer correlation to expression than
copy number variation (Figure S6). We determined Pearson
correlations between DNA methylation and gene expression in
both the MSKCC and TCGA ovarian primary tumor data sets.
Pearson correlation values .0.5 (p-values,2.061024, low meth-
ylation and high expression to high methylation and low
expression) are observed in 86 genes between the two data sets.
Prominently, the gene encoding ubiquitin B (UBB) shows a high
correlation between methylation and expression in both data sets
and RAB25 a known ovarian cancer suspect is also found in the
TCGA data set [31,46] (Tables S2A and S2B).
Tumor Suppressor and Oncogene Identification Using
Methylation and Expression Features Associated with
Copy Number Variation
We decided to integrate all forms of the data when possible to
determine which gene candidates are affected by CNV and
methylation and have a concomitant change in gene expression.
Correlations with expression will allow us to better determine
which gene functions are potentially altered in tumor samples.
Methylation and expression gene features can identify potential
tumor suppressor and oncogenic behavior in various forms of
cancer [3]. Furthermore, this epigenetic significance can be
identified when both expression and methylation data types are
examined at amplified and deleted CNV changes. Here, we
combined methylation and expression data with CNV information
from the MSKCC data set and TCGA data set to isolate genes
with potential oncogenic and tumor suppressor features (Figure 1).
Genes with low CNV or high CNV in the MSKCC and TCGA
data sets were filtered and their methylation and expression values
identified (Figure 5). In general, a potential tumor suppressor is a
gene with suppressed expression and is either functionally altered
through mutation, epigenetically silenced or deleted in the cancer
cell. Furthermore, tumor suppressors can undergo a dual
regulation with one gene copy being deleted and the other
regulated via hypermethylation [47]. A potential oncogene can
undergo direct or indirect expression control with amplified copy
number and/or low methylation features [22,47,48]. We looked
for genes with such genomic and epigenetic features (Figure 1). We
investigated altered expression by tumor sample to normal sample
expression ratios (Figure 5, Table S5). Over and under expression
thresholds for tumor to normal ratios were determined by the top
25% and bottom 25% of the entire ratio distribution, respectively.
Thresholds capturing the extreme 25% distributions within low
and high methylation were used for both the MSKCC and TCGA
data sets. We isolated 126 genes in the MSKCC data set with
tumor suppressor properties of low CNV, low tumor to normal
expression ratios and were hypermethylated (Figure 5B). When
compared to both the methylation and expression values among
the normal data samples, 114 out of these 126 genes had p-values
below 561022 (results for all genes from this analysis are found in
Tables S5, S2A and S2B). The classic tumor suppressor RB1
(retinoblastoma protein, p-value 2610216) and the tumor
suppressor BIK (Bcl-2-interacting killer, apoptosis inducing
protein, p-value 1610213) are among this feature class of gene.
A similar analysis with the TCGA data set (Figure 5A) yields 54
genes with potential tumor suppressor behavior among genes with
deleted CNV with all but 11 genes having a normal to tumor p-
value of,0.05. Examining genes with oncogenic properties such as
high tumor to normal expression ratios, high CNV and low
methylation we find 33 genes in the MSKCC data set and 285 in
Figure 4. Distribution of gene expression per copy number
variation from ovarian cancer tumor cells. As gene copy number
variation increases from deletion to amplification the mean gene
expression also increases in both the MSKCC (blue line) and TCGA
(green line) data sets.
doi:10.1371/journal.pone.0028503.g004
Figure 3. MOMA methylation in ovarian cancer tumors. The tumor:normal ratio percentage for MOMA methylation per gene from 42 ovarian
cancer tumor samples and 7 tissue normal samples is outlined per chromosome. For each sample the mean methylation value is calculated from the
maximum MOMA value per probe that incorporates the gene promoter region. MOMA methylation data covered 11,978 gene promoter regions.
Prominent hypermethylation (red) and hypomethylation (green) genes are labeled and provided in Table S2.
doi:10.1371/journal.pone.0028503.g003
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the TCGA data set (Figure 5C–D). A total of 611 genes were
identified in both data sets using tumor suppressor and oncogenic
gene features (Figure 1). Genes previously found as over expressed
in ovarian or other cancers were captured as also having over
expression and low methylation properties in ovarian cancer.
These genes with oncogenic features from either data set were
GSK3B, MMP9, ATAD2, MCM2 and UBE2C. Importantly, we
discover CDCA8 (member of the chromosomal passenger
complex), ATAD2 (AAA family protein implicated in cell
proliferation), BOP1 (resides on 8q24 similar to the MYC loci)
and EIF2C3 (involved in RNA interference) within both data sets
for genes with oncogenic properties of high expression from copy
number amplification and low methylation despite low overlap-
ping coverage of genes with all three feature modalities between
the MSKCC and TCGA data sets (2703 genes have all three
modes of data within both data sets).
In addition, we show all MSKCC predicted genes (ranked by
percentile by their FDR p-value,0.05) per chromosome with
relation to the ROMA probe copy number variation sample
frequency (Figure 6). Regions of amplification and deletion are
shown along with the number of genes with significant expression
and methylation differences from normal. In the MSKCC data set
941 genes were identified with significant changes from normal
(based on Euclidean distance measurements as described in
Methods) in both DNA methylation and expression in amplified
and deleted copy number loci, 25% (238) of which were also
discovered using the tumor suppressor and oncogene gene features
protocol. Therefore, we illustrate how loci with minor CNV
frequency among tumor samples can still contain significantly
altered expression and methylation gene features such as seen in
chromosomes 2, 6, 10 and 12 (Figure 6). These specific gene
identifications within less frequent aberrant loci can potentially
lead to a better understanding of direct functional gene
contributions in ovarian subtype cancer networks. Finally, in
order to identify likely functional and pathway changes captured
by our feature based gene analysis we tested the membership of
predicted MSKCC genes in each feature class within a total of 173
KEGG biological pathways. Performing a KEGG pathway
enrichment analysis on the predicted MSKCC data set genes
within each feature class identifies KEGG pathways associated
with cancer; endometrial cancer (hsa05213), ErbB signaling
pathway (hsa04012), amino acid metabolism (hsa00340), epithelial
cell signaling in h. pylori infection (hsa0512) and regulation of actin
cytoskeleton (hsa4810) (Figure S7).
Epigenetics and Genomics of Known Tumor Suppressors
and Oncogenes
Our Wilcoxon rank analysis revealed correlations for expression
and CNV for the oncogenes CCNE1, KRAS, MLL4 and MYC,
while our methylation/expression per CNV screen significantly
Table 2. Selected ovarian cancer genes captured by Wilcoxon rank test based on copy number variation and expression data*.
Gene Name p-value Chr. Position Gene Function
TCGA Data Set
POP4 3.53e-16 19 34789009 Component of ribonuclease P.
C19orf2 1.09e-14 19 35125264 RPB5 binding protein.
CCNE1 1.56e-14 19 34995400 Cyclin E1, ovarian cancer marker.
PAF1 7.42e-10 19 44568109 RNA polymerase II-associated factor.
KRAS 3.29e-09 12 25249446 GTPase signal transduction.
UQCRB 1.96e-08 8 97398479 Ubiquinol-cytochrome c reductase binding protein.
NFKBIB 7.88e-08 19 44082454 NF-k-B inhibitor.
PHF20L1 1.99e-07 8 133856785 PHD finger protein 20- like 1.
CASC1 1.09e-05 12 25152489 Lung adenoma susceptibility 1-like protein.
NDRG1 8.11e-05 8 134318595 N-myc downstream-regulated gene 1 protein.
MYC 1.23e-03 8 128817496 Myc proto-oncogene protein, transcription factor.
MTSS1 1.91e-02 8 125632208 Metastasis suppressor protein 1.
MSKCC Data Set
POP4 4.16e-04 19 34789009 Component of ribonuclease P.
CCNE1 1.97e-03 19 34995400 Cyclin E1, ovarian cancer marker.
FOXJ3 5.88e-03 1 42414796 Forkhead box protein.
CEBPG 1.03e-02 19 38556448 CCAAT enhancer binding protein.
C19orf2 2.29e-02 19 35125264 RPB5 binding protein.
UQCRB 2.42e-02 8 97398479 Ubiquinol-cytochrome c reductase binding protein.
MYCBP 2.73e-02 1 39101222 c-MYC binding protein.
MLL4 2.82e-02 19 40900760 Histone-lysine N-methyltransferase.
STK3 3.33e-02 8 99536036 Serine/threonine-protein kinase 3.
PHF20L1 3.57e-02 8 133856785 PHD finger protein 20- like 1.
EBAG9 4.73e-02 8 110621104 Estrogen receptor-binding fragment-cancer associated protein.
OXR1 4.76e-02 8 107739211 Oxidation resistance protein.
*Results of Wilcoxon Rank test with BH correction of selected genes in ovarian cancer tumor samples. Italics indicate genes captured from both data sets.
doi:10.1371/journal.pone.0028503.t002
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predicts the tumor suppressor RB1. We were therefore curious to
understand how all known functional cancer genes were affected
by genomic and epigenetic disturbances in ovarian cancer. We
analyzed the CNV, methylation and expression data of known
tumor suppressors, oncogenes and ovarian cancer biomarkers or
cancer related genes. We curated from literature a list of known
genes implicated in ovarian cancer or shown to be significant in
cancer pathogenesis [3,4,7,16,23,31,49]. We then compiled the
methylation and expression properties per copy number variation
for each of these genes (Table 3 presents MSKCC data, Tables
S2A, S2B and S6 show all data). As suspected, many genes exhibit
varying expression values among the three states of copy number
variation (amplified, deleted or no change which we term neutral –
Table 3, Table S6). Correlating changes of CNV and expression
can be seen in genes of the ovarian cancer 19q amplicon [50]
CCNE1 (r = 0.73) and AKT2 (r = 0.66), suggesting functional
variation within the ovarian cancer sample population. Again,
significant deletion frequency of RB1 (67%–83%) is observed in
both the TCGA and MSKCC data set, respectively. Furthermore,
the tumor suppressors PTEN, TP53, DAB2, CDKN2A, PLAGL1,
PEG3, RPS6KA2, NF1, BRCA1, BRCA2 and WWOX, all show
$50% deletion among primary ovarian tumor samples. Amplifi-
Figure 5. Oncogenic and tumor suppressor features in ovarian cancer. We isolated genes (all points) with extreme copy number variation
from the TCGA (A and C) and MSKCC (B and D) data sets. Methylation and tumor to normal expression ratio was then compared for genes at low
CNV (A and B) and high CNV (C and D). Genes with oncogenic features (blue ovals; high expression and low methylation) and tumor suppressor
features (red ovals; low expression and high methylation) were identified (Table 3).
doi:10.1371/journal.pone.0028503.g005
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cation of known oncogenes was less profound however MYC,
PIK3CA, ETV6, AURKA, EIF5A2, NOTCH3, and KRAS
exhibit $20% sample frequency. BRCA1 and BRCA2 show
unvarying methylation and expression results at all copy number
variation thresholds, plus methylation and expression levels are
consistent with normal tissue samples. CDC25A shows approxi-
mately 30% deletion among ovarian tumor samples with
unvarying methylation levels and expression correlation with
deletion. Methylation and expression for the tumor suppressor
CDKN2A is highly correlated (r = 0.79) and exhibits significant p-
values (,1.0610215) over the range of copy number variation. A
concomitant loss of expression with both methylation and copy
number variation is also observed for CDKN2A. When examining
oncogenes we see the methylation/expression correlation with
CNV for NOTCH3 (p-value,7.561026; the p-values are
determined from Euclidean distance values of methylation and
expression between normal and tumor as described in methods)
RAB25 (p-value ,5.461023), and AURKA (p-val-
ue,1.2610210). For all three genes methylation decreases and
expression increases with increased copy number. Finally, looking
at cancer related genes, we find a distinct correlation between copy
number variation and expression for MLH1 (r = 0.563) and
separately the isocitrate dehydrogenase genes. MLH1, a compo-
nent of the DNA mismatch repair complex, is hypomethylated in
samples with deleted CNV suggesting an epigenetic regulation
mechanism to increase expression within a loss in gene copy.
IDH1 and IDH2, as well as the IDH3 isoforms show positive
correlations between expression and copy number variation,
ranging from r= 0.732 for IDH2 to r = 0.504 for IDH1. We also
see differences in methylation (p-values,6.3161027) between
tumor and normal samples for all IDH genes, as previously
reported in glioblastoma [33]. However only IDH3B shows
significant differences (p-values,7.2610210) for methylation and
expression at varying copy number. We suggest that expression
changes in the IDH genes in ovarian cancer can result from a
contribution by copy number variation rather than strictly
promoter methylation changes.
Discussion
DNA copy number alterations are a common occurrence in all
cancers. Specific chromosomal regions and focal points favor
either gains or losses in DNA among cancer types [4,7]. These
amplifications and deletions are shown to include tumor
suppressors and oncogenes. In addition, DNA methylation
exhibits redistribution within a cancer genome [20,22,29]. Often
times the copy number and DNA methylation profiles are
generated as a static representation of a particular cancer’s whole
genome aberrations. However, the amplitude of specific gene
function within ovarian cancer is often highly variable between
tumor samples [3]. It is therefore essential to accurately determine
each gene’s individual functional state within its cancer environ-
ment. Here, we not only looked at whole genome patterns of copy
number aberrations and methylation but also focus on sample
specific CNV and methylation properties for altered genes to
provide a better understanding of ovarian cancer gene function-
ality. We first separately present data of DNA structural variation
and DNA methylation changes in ovarian tumors and then
combine the two modalities with expression data to identify how
these aberrations may affect individual gene function within the
tumor population.
We first analyzed the DNA copy number variation of primary
ovarian tumors from 42 individuals and compared our findings to
The Cancer Genome Atlas data set for ovarian cancer [31]. In
analysis of CNV segmentation changes in our 42 tumor samples,
DNA variability is shown to be most prevalent in chromosomes 1,
2, 4, 8, 9 and 19. We have shown a large variability in
amplification and deletion breakpoint loci in ovarian tumors and
identified chromosomal areas of frequent copy number variations.
We see a high level of amplification frequency in known oncogenic
regions containing MYC (chromosome 8), CCNE1 (chromosome
19) and frequent deletions are found in chromosome arms 4q, 16q,
and 17p [16,51]. Similarly to the TCGA data analysis ROMA
detected high frequency copy losses in PTEN, RB1, and NF1. We
also show the known but previously unreported in primary ovarian
tumors amplification of the MCL region of chromosome 1q21.1-
q21.2 [4,31] and previously unreported deletions in the IDH2 and
IDH3 region of chromosome 15. A total of 983 genes are included
in amplified and deleted regions. A strong correlation of
expression with copy number variation has been reported in
ovarian cancer [52]. Here, we primarily focused on quantifying
this correlation at varying CNV levels for the purposes of
functional annotation. Most significant changes of expression
occur at extreme CNV. We show that copy number variation has
a strong effect on expression in primary ovarian tumors for 156
genes. Notable genes with correlated CNV and expression include
MYC, CCNE1, KRAS, NDRG1, MLL4, MTSS1, C11orf30,
MLH1 and CEPBG. Genes identified in the MSKCC data set
were from similar genomic loci as those found in the TCGA data
set. Five genes were predicted from both data sets: CCNE1,
POP4, UQCRB, PHF20L1 and C19orf2. In addition isocitrate
dehydrogenase isoforms IDH2 (chr15), IDH3A (chr15), and
Figure 6. Ranking of significantly expressed and methylated genes with copy number variation. Predicted MSKCC data set genes (green
circle) with changes in methylation and expression are overlayed a genome wide stair-plot of ROMA probe sample frequencies per deletion and
amplification (blue line). Each predicted gene is percentile ranked according to its FDR p-values (,0.05) between normal and tumor samples.
doi:10.1371/journal.pone.0028503.g006
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IDH3B (chr20) show correlated expression to CNV. The IDH1
and IDH2 genes are mutated in glioblastoma and AML cancer
patients. IDH1 has been implicated as a prognosis positive
biomarker in glioblastoma and AML IDH1/2 mutants show
hypermethylation in comparison to other AML subtypes [53,54].
All the isocitrate dehydrogenase genes exhibit deleted CNV in
ovarian cancer samples (ranging from 14%–52%, Table 3). Here,
we show for both the IDH2 and IDH3A/IDH3B genes expression
is mainly correlated in tumor samples exhibiting deleted copy
number to normal copy number.
Next, we examined genome wide DNA methylation in ovarian
tumors. DNA methylation alterations are a significant feature of
Table 3. Copy number variation derived methylation and expression of tumor suppressors and oncogenes in ovarian cancer*.
MSKCC Data Set
Gene Copy Number Variation CNV Frequency Seg.mean Methylation Expression
Tumor Suppressors
RB1 Amplified 0.00 0.00 0.00 0.00
RB1 Neutral 0.17 0.03 0.98 5.04
RB1 Deleted 0.83 20.12 0.99 4.66
PTEN Amplified 0.00 0.00 0.00 0.00
PTEN Neutral 0.42 0.03 1.03 5.43
PTEN Deleted 0.58 20.04 1.04 5.32
TP53 Amplified 0.00 0.00 0.00 0.00
TP53 Neutral 0.07 0.06 0.97 5.33
TP53 Deleted 0.93 20.10 0.90 4.89
PLAGL1 Amplified 0.03 1.06 1.13 10.36
PLAGL1 Neutral 0.20 0.04 1.14 5.73
PLAGL1 Deleted 0.77 20.05 1.14 4.94
Oncogenes
MYC Amplified 0.13 0.69 0.96 8.28
MYC Neutral 0.80 0.16 0.98 7.61
MYC Deleted 0.07 20.04 0.98 8.26
AKT2 Amplified 0.03 0.56 1.09 4.93
AKT2 Neutral 0.45 0.06 1.09 4.51
AKT2 Deleted 0.52 20.09 1.07 4.50
FGFR1 Amplified 0.02 0.60 1.25 6.83
FGFR1 Neutral 0.60 0.09 1.12 6.44
FGFR1 Deleted 0.38 20.12 1.13 6.09
CCNE1 Amplified 0.12 0.68 1.17 8.44
CCNE1 Neutral 0.42 0.09 1.14 7.59
CCNE1 Deleted 0.45 20.05 1.11 6.72
Biomarkers/Cancer-Related
WFDC2 Amplified 0.05 0.56 0.94 10.30
WFDC2 Neutral 0.70 0.11 0.97 11.21
WFDC2 Deleted 0.25 20.03 0.98 9.55
PIAS3 Amplified 0.03 0.86 1.08 6.75
PIAS3 Neutral 0.76 0.07 1.11 5.95
PIAS3 Deleted 0.21 20.02 1.17 5.72
IDH3B Amplified 0.00 0.00 0.00 0.00
IDH3B Neutral 0.72 0.08 0.99 7.10
IDH3B Deleted 0.28 20.04 1.01 6.91
IDH3G Amplified 0.03 0.50 0.97 6.83
IDH3G Neutral 0.82 0.16 0.97 6.98
IDH3G Deleted 0.15 20.03 1.00 6.51
*Selected ovarian cancer related tumor suppressor and oncogene epigenetic data is presented from the MSKCC data set. The frequency of each gene found in an
amplified, neutral or deleted state based on CNV thresholds is provided. The seg.mean threshold for amplified was set at $0.50 and for deleted at ,0.00. Neutral was
defined as not within the amplified or deleted thresholds. And the average seg.mean, methylation and expression values for those CNV states is shown. A complete
table with the full summary from both data sets is present in Table S6.
doi:10.1371/journal.pone.0028503.t003
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the cancer genome [1,23]. The protocadherin gene cluster of
chromosome 5 has been shown to be frequently hypermethylated
and silenced in various forms of cancer [55,56]. We see broad
hypermethylation for both the PCDHa and PCDHb loci in
ovarian cancer as well. We also observe increased levels of
methylation in other cancer related genes e.g. ALX3 and
PHOX2B both implicated in neuroblastoma [57,58]. Decreased
levels of methylation are seen in genes such as calcyphosin which
exhibits oncogenic properties in endometrial cancer [59], lactate
dehydrogenase which when inhibited impairs cell proliferation via
the Warburg effect of aerobic glycolysis in cancer cells [60] and
DUB3, the CDC25A stabilizing protein ubiquitin hyrdolase [61]
which has been shown to rescue CDC25A from proteasomal
degradation and promote an oncogenic induction response [62].
Hypomethylation with subsequent cellular rise of DUB3 can
therefore be a candidate for the cellular regulation of CDC25A
protein levels and CDC25A linked oncogenesis.
Finally, to identify genes with a more direct genomic and
epigenetic effect on the function of the cancer cell, we directed our
focus on the combined gene features of copy number, methylation
and expression. Tumor suppressors and oncogenes are often
implicated by their transcriptional abnormalities in the cancer cell.
It is of interest to understand which tumor suppressors and
oncogenes play a direct role in a particular cancer among all genes
affected by genomic aberrations. A certain tumor suppressor or
oncogene function may be gained or silenced at varying
frequencies by different epigenetic and genomic conditions within
the tumor sample population. Examining these properties and
their affects on gene expression can provide better insight into
identifying which genes are most responsible to the pathology of
the tumor. We therefore formulate a set of predictive features
based on genomic and epigenetic properties of the tumor that can
be indicative of altered function for tumor suppressors and
oncogenes in the cancer genome (Figure 1). Low expression of
various tumor suppressors in cancer cells can be a result of deleted
copy number or silencing by promoter hypermethylation. While
amplification and promoter hypomethylation can play a role in the
over expression of oncogenes. Conversely, a particular known
oncogene may be deleted in a particular cancer lessening its
pathogenic role within that cancer or an individual sample.
Interestingly, for highly amplified genes, a high level of
methylation accompanied by low expression could indicate altered
tumor suppressor function in the cancer cell. In highly amplified
genes, low level methylation and high expression would indicate
oncogenic features in a cancer cell. We therefore utilized samples
with extreme copy number variations and examined the
methylation and expression changes of genes within these aberrant
loci to identify potential tumor suppressors and oncogenes.
Examining both our primary MSKCC tumor sample data set
and the TCGA data set, we discovered 180 genes with tumor
suppressor features of low expression with copy number deletion
and high methylation. These features are characteristic of known
classic tumor suppressors among which the established tumor
suppressor RB1 (retinoblastoma protein) was captured. Addition-
ally we find another 48 genes with elevated copy number but low
expression and high methylation. For oncogenic epigenetic gene
features we discover 318 genes within amplified loci and 65 within
deleted copy number loci between the two data sets. Several genes
discovered in ovarian cancer tumors with these specific tumor
suppressor and oncogenic features have been previously implicat-
ed in other cancers and are now shown to have additional
methylation and copy number variation properties. Furthermore,
25% of the genes captured with tumor suppressor and oncogenic
gene features were represented in 941 MSKCC data set genes
(Figure 6) with significant changes in methylation and expression
per CNV. Seven genes were identified from both the MSKCC and
TCGA data sets that contained strong correlations for methylation
dependent expression exhibited at varying copy number aberra-
tions; CDCA8, ATAD2, CDKN2A, RAB25, AURKA, BOP1 and
EIF2C3. Four of these seven genes (CDCA8, ATAD2, CDKN2A,
AURKA) have direct functional relationships of binding and
regulation with other experimentally established oncogenes and
tumor suppressors such as TP53, RB1, MYC and E2F1
[63,64,65,66]. Thereby indicating a potential functional cancer
module (Figure S8) that can be further computationally and
experimentally targeted. Using genomic features specific to
aberrations found in tumor sample data captures previously
identified tumor suppressors and oncogenes in addition to genes
associated with these biomarkers. This genomic and epigenetic
function-based feature approach identified genes in cancer
pathways such as endometrial cancer, ErbB signaling pathways,
epithelial cell signaling and actin cytoskeleton regulation. This type
of primary gene function identification approach can provide a
base feature set for further machine-learning cancer network
prediction protocols.
In addition, cancer genes exhibiting contradictory tumor
suppressor or oncogenic epigenetic features in ovarian cancer
may provide clues into the regulatory pathways within ovarian
cancer. Of note, predicted within the MSKCC data set tumor
suppressor features is the established oncogenic transcription
factor STAT3 [67,68,69]. Here we see significant STAT3 deletion
($73% sample frequency) contributing to a potential heterozygous
gene copy loss in both the TCGA and MSKCC data sets.
Furthermore, within samples containing a low copy number of
STAT3 gene, slightly higher methylation and lower expression
values are observed. This may suggest a decreased role for STAT3
in the oncogenic function within ovarian tumors. Therefore,
epigenetic and genomic specific gene features are at the strength of
our predictions and can be used to i) predict novel gene functions
in ovarian cancer and ii) elucidate or verify the direct cancer
functioning role for previously implicated tumor suppressors or
oncogenes. We therefore decided to examine many known cancer
oncogenes and tumor suppressors for varying levels of regulation
among tumor samples. For instance, the ovarian cancer oncogenes
CCNE1 and RAB25 [3,70] show significant methylation and
expression correlation for both amplified and deleted copy number
aberrations. The expression levels of these cancer functioning
genes differs between samples and the modes of epigenetic
regulation exhibit different levels of frequency [3]. Each gene
affecting the growth of the tumor is not evenly implicated in all
samples. We therefore attempted to illustrate these genomic and
epigenetic sample irregularities (such as observed in PLAGL1,
CCNE1 and PIAS3) for many of the known ovarian cancer genes
(Table 3, Tables S2 and S6). Sample specific feature analysis of
identical gene combinations and modules at amplified, neutral or
deleted copy number with corresponding epigenetic regulatory
features can be used to identify ovarian cancer heterogeneity and
the driving genes contributing it. Application of this gene function
diversity can be further studied using clinical information for each
sample, thereby combining cancer gene modules with each
samples’ clinical features. The development of this type of
knowledge base of gene features in a cancer population will better
help identify subtype specific tumor function.
The continuing increase of experimental epigenetic data from
various tumor samples offers the ability to computationally search
for putative genes with properties in the proliferation of cancer
cells. Here we performed a coarse-grained bioinformatics whole
genome evaluation of epigenetic features in ovarian cancer tumor
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cell from two separate platforms covering over 11,500 genes. We
demonstrate ovarian cancer specific epigenetic regulation of
previously identified cancer genes and cancer biomarkers.
Furthermore, we were also able to implicate genes with tumor
suppressor and oncogenic epigenetic properties specific to ovarian
cancer tumors that have not been previously reported. Examina-
tion of multiple cancer epigenetic modalities will help segregate
cancer specific genes from randomly altered cancer genes and can
possibly elucidate the genetic mediators of ovarian tumorigenesis.
The focus on gene combinations with specific copy number
aberrations per individual tumor sample plus their methylation
and expression properties within those samples allows for the
better understanding and eventual identification of tumor type
specific cancer pathways.
Supporting Information
Figure S1 Copy number variability in ovarian cancer
tumor samples. A) Variability per chromosome of all ROMA
derived CBS segmentation values for 42 tumor samples in the
MSKCC data set is shown. B) The mean value (horizontal straight
bar) of CNV segmentation values per chromosome and standard
deviation (error bars) from 42 tumor samples.
(TIF)
Figure S2 Copy number variation in TCGA and ROMA
samples for ovarian cancer specific genes. Presented are
four examples of copy number variation analyzed per gene (see
methods) from TCGA tumor CNV data (open grey circles) and from
MSKCC data set ROMA array tumor samples (filled black boxes).
CBS segmentation mean (Seg.Mean) values per sample are plotted for
four known ovarian cancer significant genes. Amplification and
deletion sample comparisons between TCGA and ROMA segmen-
tations are shown for A) MYC,B) TP53,C) CCNE1 andD) NCOA3.
(TIF)
Figure S3 Cumulative distribution of gene expression
per copy number variation. The cumulative distribution
function (Fn(x) = P(X#x)) for expression is plotted for genes with
high (red line) and low (green line) copy number variation
discovered from ROMA analysis (A) and found in the TCGA data
set (B). Maximum difference in expression distribution between
low and high copy is 7% in the TCGA data set and 17% in the
MSKCC data set.
(TIF)
Figure S4 Expression of the MYC gene in ovarian tumor
and normal samples in the TCGA data set. The expression
of the gene MYC in ovarian tumor samples and normal samples as
identified in the TCGA data set. Expression values are shown for
samples with amplified CNV for MYC (left panel), deleted CNV
for MYC (center panel) and for normal tissue (right panel).
Colored bar shows the expression mean for each condition.
(TIF)
Figure S5 Genes captured by Wilcoxon rank test in
ovarian cancer tumor samples. The Wilcoxon Rank test was
performed on the ovarian cancer tumor TCGA data set. The test
ranked expression levels of genes among samples with high and
low copy number gene values. With a low CNV seg.mean
threshold set at 20.50, the total genes captured was dependent on
the high CNV threshold. Shown are the total genes captured (filled
in square, dotted line) and number of genes with a FDR,0.50
(filled in circle, solid line) by the Wilcoxon rank test at CNV values
of 0.80, 1.0 and 1.25. A total of 54 to 1114 genes with FDR,0.50
is identified using CNV threshold values of 0.80 to 1.25.
(TIF)
Figure S6 Expression correlation with copy number
variation or methylation. Correlation value distribution per
gene of expression to copy number variation (CNV-Expression,
green line) and methylation (Methylation-Expression, red line) are
shown as a proportion of total genes analyzed for TCGA (A) and
ROMA-MOMA MSKCC data (B).
(TIF)
Figure S7 KEGG pathway enrichment analysis. A KEGG
pathway enrichment analysis defined by hypergeometric distribu-
tion was performed on the genes predicted in the MSKCC data set
for each genomic and epigenetic feature class for oncogenes and
tumor suppressors. Amp. abbreviation defines the amplified CNV
feature set and Del. abbreviation identifies genes in the deleted
CNV feature set. The significantly identified KEGG pathways are
presented for each feature class.
(TIF)
Figure S8 Network for ovarian cancer identified tumor
suppressors and oncogenes. Genes with a strong correlation
for methylation dependent expression exhibited at varying copy
number aberrations identified in both the MSKCC and TCGA
data sets include CDCA8, ATAD2, CDKN2A, and AURKA
(blue circles). Here are depicted the functional relationships
(regulating and binding) for those four genes with other known
tumor suppressors and oncogenes.
(TIF)
Table S1 MOMA identified hypomethylated and hyper-
methylated genes in ovarian cancer tumor samples for
MSKCC data set. Tumor to Normal methylation ratios are
presented for hypomethylated and hypermethylated genes in 42
MSKCC samples from the MOMA platform. All MOMA data
can be found in the GEO database (http://www.ncbi.nlm.nih.
gov/geo/) for the subseries reference identifier GSE27940.
(XLS)
Table S2 Correlation values per gene for copy number
variation, methylation, and expression. Correlation values
for gene expression with copy number variation and separately
methylation are presented for each gene in the A) MSKCC data set
and B) TCGA data set. Significance values of Euclidean distances
calculated between normal and tumor samples for methylation and
expression data points for all genes in all samples and either in a
deleted or amplified state is provided in the final three columns.
(XLS)
Table S3 Ovarian cancer genes with large expression
deviation within TCGA data set. Genes with high and low
CNV in at least 20% of TCGA data set samples are presented for
expression deviations from normal.
(XLS)
Table S4 All genes captured by Wilcoxon rank test
based on copy number variation and expression data.
Results of Wilcoxon rank test with BH correction of selected genes
in ovarian cancer tumor samples from both MSKCC and TCGA
data sets. Bold indicate genes captured from both data sets.
(XLS)
Table S5 Predicted genes with copy number variation,
methylation and expression for tumor suppressor and
oncogene features in both MSKCC and TCGA data sets.
Genes predicted from tumor suppressor and oncogene genomic
and epigenetic features are shown. Location for each gene and
epigenetic and genomic data values are shown. Thresholds used
for each individual platform are provided per feature set.
(XLS)
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Table S6 Copy number derived methylation and ex-
pression of tumor suppressors and oncogenes. Methyla-
tion and expression properties per copy number variation (from
both the MSKCC and TCGA data sets) a presented for a curated
list of known genes implicated in ovarian cancer or shown to be
significant in cancer pathogenesis.
(XLS)
Analysis S1 Supporting analysis scripts.
(PDF)
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